Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIV

Journal of Infectious Diseases

Volumn 202, Issue 2, 2010, Pages 291-301

  Crain, Marilyn J ^a   Chernoff, Miriam C ^b   Oleske, James M ^d   Brogly, Susan B ^b   Malee, Kathleen M ^e   Borum, Peggy R ^f   Meyer, William A ^g   Mitchell, Wendy G ⁱ   Moye, John H ^h   Ford Chatterton, Heather M ^j   Van Dyke, Russell B ^k   Seage, George R ^b,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Dentistry of New Jersey   (United States)

^e CHILDREN'S MEMORIAL HOSPITAL   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^h Institute of Child Health   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^k TULANE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD MORTALITY; CLINICAL TRIAL; COHORT ANALYSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL DYSFUNCTION; PERINATAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; SCHOOL CHILD; VIROTHERAPY; MORTALITY; NEWBORN; PATHOPHYSIOLOGY; PREGNANCY; PRENATAL EXPOSURE; REGRESSION ANALYSIS; UNITED STATES;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MALE; MITOCHONDRIAL DISEASES; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; STAVUDINE; UNITED STATES; ZIDOVUDINE;

EID: 77954577898     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/653497     Document Type: Article

References (48)

1. Miller TL, Easley KA, Zhang W, et al. Maternal and infant factors associated with failure to thrive in children with vertically transmitted human immunodeficiency virus-1 infection: the prospective, P2C2 human immunodeficiency virus multicenter study. Pediatrics 2001; 108: 1287-1296.
2. Miro O, Lopez S, Pedrol E, et al. Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy. Antivir Ther 2003; 8:333-338.
3. Nerurkar PV, Pearson L, Frank JE, Yanagihara R, Nerurkar VR. Highly active antiretroviral therapy (HAART)-associated lactic acidosis: in vitro effects of combination of nucleoside analogues and protease inhibitors on mitochondrial function and lactic acid production. Cell Mol Biol (Noisy-le-grand) 2003; 49:1205-1211.
4. Cherry CL, Nolan D, James IR, et al. Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIVinfected individuals. J Acquir Immune Defic Syndr 2006; 42:435-440.
5. Miro O, Lopez S, Martinez E, et al. Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis 2004; 39:710-716.
6. Rotig A, Munnich A. Genetic features of mitochondrial respiratory chain disorders. J Am Soc Nephrol 2003; 14:2995-3007. (Pubitemid 37509278)
7. Claessens Y-E, Cariou A, Monchi M, et al. Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. Crit Care Med 2003; 31:1042-1047.
8. Chinnery PF, Turnbull DM. Epidemiology and treatment of mitochondrial disorders. Am J Med Genet 2001; 106:94-101.
9. Gerschenson M, Brinkman K. Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion 2004; 4:763-777.
10. Hulgan T, Haas DW. Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity. J Infect Dis 2006; 194: 1471-1474.
11. Hulgan T, Haas DW, Haines JL, et al. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS 2005; 19:1341-1349.
12. Moslemi AR, Darin N. Molecular genetic and clinical aspects of mitochondrial disorders in childhood. Mitochondrion 2007; 7:241-252.
13. Capps GJ, Samuels DC, Chinnery PF. A model of the nuclear control of mitochondrial DNA replication. J Theor Biol 2003; 221:565-583.
14. Lee H, Hanes J, Johnson KA. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003; 42:14711-14719.
15. Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004; 18:137-151.
16. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16:2165-2173.
17. Chene G, Amellal B, Pedrono G, et al. Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy. AIDS Res Hum Retroviruses 2007; 23:54-61.
18. McComsey GA, Kang M, Ross AC, et al. Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy. HIV Clin Trials 2008; 9:126-136.
19. Lonergan JT, McComsey GA, Fisher RL, et al. Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2004; 36: 935-942.
20. Lopez S, Miro O, Martinez E, et al. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir Ther 2004; 9:47-55.
21. Maagaard A, Holberg-Petersen M, Kollberg G, Oldfors A, Sandvik L, Bruun JN. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients. Antivir Ther 2006; 11:601-608.
22. McComsey GA, Walker UA. Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies. Mitochondrion 2004; 4:111-118.
23. Reiss P, Casula M, de Ronde A, Weverling GJ, Goudsmit J, Lange JM. Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors. HIV Med 2004; 5:11-14
24. Saitoh A, Fenton T, Alvero C, Fletcher CV, Spector SA. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2007; 51:4236-4242.
25. Saitoh A, Haas RH, Naviaux RK, Salva NG, Wong JK, Spector SA. Impact of nucleoside reverse transcriptase inhibitors on mitochondrial DNA and RNA in human skeletal muscle cells. Antimicrob Agents Chemother 2008; 52:2825-2830.
26. Brogly S, Williams P, Seage GR III, Oleske JM, Van Dyke R, McIntosh K. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA 2005; 293:2213-2220.
27. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 2007; 21:929-938.
28. Brogly S, Williams P, Seage GR III, Van Dyke R. In utero nucleoside reverse transcriptase inhibitor exposure and cancer in HIV-uninfected children: an update from the Pediatric AIDS Clinical Trials Group 219 and 219C cohorts. J Acquir Immune Defic Syndr 2006; 41:535-536.
29. Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 2006; 296:292-300.
30. Brown EG, Wood L, Wood S. The Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf 1999; 20:109-117.
31. Brown EG. Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART. Drug Saf 2002; 25:445-452.
32. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354:1084-1089. (Pubitemid 29452821)
33. Wolf NI, Smeitink JA. Mitochondrial disorders: a proposal for consensus diagnostic criteria in infants and children. Neurology 2002; 59: 1402-1405.
34. Caldwell B, Oxtoby M, Simonds RJ, Lindegren ML, Rogers M. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43:1-10.
35. Skladal D, Halliday J, Thorburn DR. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 2003; 126: 1905-1912.
36. Schaefer AM, McFarland R, Blakely EL, et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol 2008; 63:35-39.
37. Scaglia F, Towbin JA, Craigen WJ, et al. Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics 2004; 114:925-931.
38. Skladal D, Sudmeier C, Konstantopoulou V, et al. The clinical spectrum of mitochondrial disease in 75 pediatric patients. Clin Pediatr (Phila) 2003; 42:703-710.
39. Morava E, van den Heuvel L, Hol F, et al. Mitochondrial disease criteria: diagnostic applications in children. Neurology 2006; 67:1823-1826. (Pubitemid 44900760)
40. Cote HC. Mechanisms of antiretroviral therapy-induced mitochondrial dysfunction. Curr Opin HIV AIDS 2007; 2:253-260.
41. Dagan T, Sable C, Bray J, Gerschenson M. Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence? Mitochondrion 2002; 1:397-412.
42. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003; 2:812-822.
43. Polo R, Martinez S, Madrigal P, Gonzalez-Munoz M. Factors associ ated with mitochondrial dysfunction in circulating peripheral blood lymphocytes from HIV-infected people. J Acquir Immune Defic Syndr 2003; 34:32-36.
44. Wohl DA, McComsey G, Tebas P, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006; 43:645-653.
45. LewisW, Kohler JJ, Hosseini SH, et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. AIDS 2006; 20:675-684.
46. Gerschenson M, Shiramizu B, LiButti DE, Shikuma CM. Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals. Antivir Ther 2005; 10(suppl 2):M83-M89.
47. Boyd MA, Carr A, Ruxrungtham K, et al. Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. J Infect Dis 2006; 194:642-650.
48. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46:716-723. (Pubitemid 34157656)